Envirotainer invests in Canada
24 / 10 / 2023
Secure cold chain solutions specialist Envirotainer has upgraded its Montreal station and invested in a new facility in Toronto to support Canada’s rapidly expanding biopharmaceuticals market.
In Montreal, Envirotainer’s station is now fully equipped to handle its Releye containers. Customers can now release their orders directly from the station and make returns with greater efficiency, reducing risks associated with delays, Envirotainer said, noting that it now has over 40 stations around the world that support Releye.
Available in two sizes (RAP and RLP), fully charged Releye containers can maintain a constant internal temperature for up to a week. Their light, compact design helps reduce CO2 emissions by maximising the amount of pharmaceuticals that can be transported on each flight while minimising weight.
Meanwhile, at Toronto airport, Envirotainer has moved to a larger ground handling facility with 40% more storage space and fast charging capabilities to support the Releye platform.
Niklas Adamsson, chief operating officer at Envirotainer, said the company’s investments at its Canadian stations demonstrate its commitment to making global pharmaceutical access a reality and supporting Canada’s growing biopharmaceutical sector.
“We believe these enhancements not only extend the reach of Envirotainer’s solutions but also equip our customers with cutting-edge tools to serve their clients better,” he said.
Carolyn Van Vliet, strategic account manager for Canada at Envirotainer, added: “We take great pride in serving our customers in Canada’s thriving biopharmaceutical ecosystem as they drive innovation and excellence within the industry.
“These improvements at Montreal and Toronto enable us to better support the needs of our customers while ensuring the safe and efficient transportation of life-saving biopharmaceuticals worldwide.”
Canada’s pharmaceuticals market is the ninth largest in the world, at 2.1% of the global market. This looks set to increase as the country continues to focus on innovative medicines, generic pharmaceuticals and R&D initiatives.